Not a good buy right now: price trend is bearish (down ~6.8% today) with weakening momentum (MACD negative and expanding).
No Intellectia edge today: AI Stock Picker and SwingMax both show no signal, so there’s no strong tactical reason to step in aggressively.
Fundamentals don’t support an impatient entry: revenue is barely growing while losses and EPS deterioration remain significant.
Options positioning is mixed but not convincingly bullish, and volatility is extremely elevated—this looks more like speculative trading flow than confident accumulation.
Net: avoid/exit rather than buy at $1.37 if you’re unwilling to wait for a cleaner reversal setup.
Technical Analysis
Trend/Momentum: MACD histogram -0.0112 below zero and negatively expanding → bearish momentum is strengthening.
RSI (6): 33.69 → weak/near-oversold behavior, but not showing a clear reversal signal.
Moving averages: converging → consolidation/uncertainty, but currently not signaling an uptrend.
Key levels: price $1.37 is below S1 (1.438) and near S2 (1.339) → stock is sitting in a fragile support zone; a break below ~1.34 would be technically damaging.
Pattern-based odds (provided): next day skew slightly negative; next week modestly positive—too weak to offset current downside pressure.
Sentiment read: OI put/call ~1.04 is slightly defensive (more puts than calls outstanding), while volume put/call 0.63 leans more bullish/short-term call activity.
Activity: today’s option volume is highly elevated vs the 30-day average (25x), and open interest is also elevated vs average (186x) → unusual speculative interest.
Volatility: extremely high (HV ~519%, 30d IV ~190%); IV percentile 13.2%/IV rank ~19 suggests IV is lower relative to its own recent range, but still very high in absolute terms → options are pricing large swings; not a “stable” bullish setup.
Technical Summary
Sell
6
Buy
7
Positive Catalysts
can sometimes trigger short-lived reflex rallies if support holds.
Neutral/Negative Catalysts
indicates ongoing hedging/defensive positioning by longer-horizon option holders.
Financial Performance
Latest quarter: 2024/Q3.
Revenue: $43.73M, +1.58% YoY → low growth.
Net income: -$9.68M, down -63.07% YoY → losses widened significantly.
EPS: -0.34, down -64.21% YoY → earnings power deteriorating.
Gross margin: 36.05%, up 64.84% YoY → operational bright spot, but not yet translating into improved bottom line.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so a current Wall Street consensus trend can’t be confirmed.
Practical pro view (based on available data): margin improvement could be the bull case if it leads to future loss narrowing.
Practical con view: minimal revenue growth plus worsening net losses/EPS makes it hard for analysts to argue for near-term upside without a clear turnaround catalyst.
Influential buyers/sellers: no recent congress trading data available; hedge funds and insiders are reported as neutral (no significant recent trend).
Wall Street analysts forecast CMBM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMBM is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast CMBM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMBM is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.